BC Week In Review | May 25, 2018
Clinical News

Janssen discontinues two Alzheimer's trials for BACE inhibitor

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said it is discontinuing two trials testing atabecestat (JNJ-54861911) to treat Alzheimer's disease after an evaluation showed the therapy led to elevated liver enzyme levels....
BC Week In Review | Sep 22, 2014
Clinical News

Lampalizumab: Phase III started

Roche began the identical, double-blind, sham-controlled, international Phase III Chroma (GX29176) and Spectri (GX29185) trials to evaluate 10 mg intravitreal lampalizumab every 4 or 6 weeks each in 936 patients with GA in both eyes...
BC Week In Review | Nov 25, 2013
Clinical News

Lampalizumab: Additional Phase II data

Roche's Genentech Inc. unit disclosed the details of an exploratory biomarker from the single-blind Phase II MAHALO trial evaluating lampalizumab to treat GA associated with AMD. In August, data from 129 patients in MAHALO showed...
BC Extra | Nov 19, 2013
Clinical News

Genentech details biomarkers for lampalizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed the details of an exploratory biomarker for the company's lampalizumab ( RG7417 ), which is in development to treat geographic atrophy (GA), an advanced form of dry...
BC Innovations | Sep 29, 2011
Targets & Mechanisms

Square one in CFS

The Chronic Fatigue Initiative is moving on to new approaches to identify the true cause of chronic fatigue syndrome after a consortium of American researchers failed to reproduce a 2009 study linking CFS to a...
BC Week In Review | Sep 18, 2000
Clinical News

Critical fluid inactivation regulatory update

Aphios received European Patent No. 0629135 covering a method of inactivating enveloped and non-enveloped pathogenic viruses using the company's SuperFluids critical or near-critical fluids that permeate viruses and cause them to rupture. Aphios Corp., Woburn,...
BC Week In Review | Aug 17, 1998
Company News

Aphios other research news

Aphios received a $100,000 Phase I SBIR from the National Institute of Allergy and Infectious Diseases to develop a therapeutic HIV vaccine combining its attenuated HIV particles (including HIV lacking the nef protein) and mixtures...
Items per page:
1 - 7 of 7